Search Khaleej Dailies

Saturday, February 21, 2026

RAK Ports Secures Landmark Investment from APT Global to Strengthen Project Cargo Ecosystem driven by Saqr 2.0

Ras Al Khaimah, United Arab Emirates - Friday, 20. February 2026 

RAK Ports has signed a memorandum of understanding (MoU) with APT Global, marking a major milestone in Ras Al Khaimah’s industrial growth strategy. This investment is supported by Saqr 2.0, RAK Ports’ greenfield port development designed to accommodate continued growth in the region.

APT Global will invest ~AED 50 million to develop ~700K sqft facility in RAK Maritime City. The expansion will expand their footprint to approx. ~2.0 million sqft. This will help diversify APT’s business into offshore fabrication, renewables, Shipbuilding, Oil & Gas Sector Constructions targeting Europe, United States and the Far East Asia Markets.

The ~AED 50 million fabrication facility inside RAK Maritime City Free Zone enables direct use of deepwater berths, dedicated logistics corridors, and quayside adjacent assembly, a major efficiency advantage rarely available in the region. The factory will export large volumes of oversized, out of gauge structures, aligning perfectly with Saqr 2.0’s heavy lift and project cargo ecosystem.

The expansion leverages Saqr 2.0’s ~14m draft and access to nearly 65 million sqft of Freezone within a 4 km radius. 50m wide unobstructed road corridors offer unmatched connectivity to the port. Strategically located Assembly pads within 500m of the port support last mile assembly and export of these mega structures.

Roy Cummins, CEO of RAK Ports, stated:

“This agreement reflects our commitment positioning Ras Al Khaimah as a leading hub for project cargo logistics. Saqr 2.0 unlocks projects with single shipments of ~ 35,000 metric tonne via our heavy lift pad and 50m road corridors from plot to port to provide APT Global with the world class connectivity and operational efficiencies. This project demonstrates the scale and ambition of our vision to attract global partners and set new benchmarks for project cargoes and large-scale manufacturing in the region.”

Anil Abraham, CEO of APT Global, stated:

“This MoU with RAK Ports is a strategic milestone for APT Global and underscores our long-term commitment to the UAE as a hub for advanced marine and offshore fabrication. The Saqr Port 2.0 facility strengthens our scale, ESG-led capabilities, and ability to deliver complex projects to global standards, while directly supporting the ‘Made in Emirates’ vision and the UAE’s industrial and sustainability ambitions.”



Contacts

Aarif Nazir

Email: a.nazir@rakports.ae

NAFFCO Group and MAN Truck & Bus Strengthen Strategic Partnership with Expanded MoU


 In a significant step toward advancing global firefighting and rescue capabilities, NAFFCO Group has signed an expanded Memorandum of Understanding (MoU) with MAN Truck & Bus, one of Europe’s leading commercial vehicle manufacturers.


NAFFCO Group recently welcomed the leadership team from MAN Truck & Bus to its headquarters in Dubai to further strengthen their long standing strategic relationship.


Eng. Khalid Al Khatib, Founder and Chief Executive Officer of NAFFCO Group; Ali Khalid Al Khatib, Group Managing Director of NAFFCO Group; and Mohammad Al Khatibeh, Marketing Director  Vehicles Division, hosted Friedrich Baumann (Executive Board Member), Thomas Hemmerich (Head of Sales Area International), and Mikael Lindner (Head of MEA & CIS) for high-level discussions focused on chassis innovation, vehicle integration excellence, and long term global growth.


During the visit, the expanded Memorandum of Understanding was formally signed, marking a new milestone in a partnership built on trust, engineering expertise, and a shared vision for advancing firefighting and rescue vehicle technology.


By combining NAFFCO’s expertise in advanced firefighting systems, rescue vehicle engineering, and specialized vehicle manufacturing with MAN’s cutting edge automotive engineering and chassis technology, the strengthened partnership aims to co develop next generation firefighting and rescue vehicles tailored to evolving global safety requirements.


This expanded collaboration builds upon years of successful cooperation, during which MAN chassis have served as reliable, high performance platforms for many of NAFFCO’s advanced fire trucks and rescue vehicles operating worldwide. The synergy between the two organizations has consistently delivered robust, durable, and technologically advanced vehicles designed to perform in the most demanding emergency environments.


This strengthened collaboration reflects both organizations’ commitment to innovation, quality, and the continuous advancement of firefighting and rescue solutions worldwide. As global safety challenges continue to evolve, NAFFCO Group and MAN Truck & Bus are poised to deliver smarter, more efficient, and technologically advanced firefighting and rescue vehicles setting new benchmarks for performance, reliability, and operational excellence across the global safety and mobility sectors.



Permalink

https://aetoswire.com/en/news/2002202653465


Contacts

Mohammad Al Khatibeh


info@naffco.com


0097148151111

إطلاق iCAUR V27 عالمياً للمرة الأولى من دولة الإمارات العربية المتحدة


الإطلاق الرسمي لعلامة iCAUR، مع ترسيخ مكانة دولة الإمارات كسوق استراتيجية عالمية رئيسية

العلامة تستهدف فئة الشباب ومن يتمتعون بروح الشباب

طراز V27 يعيد تعريف مفهوم السيارات الرياضية المتعددة الاستخدامات الكلاسيكية، بتصميم خالد وأداء ديناميكي مدعوم بأحدث التقنيات

 


أعلنت علامة iCAUR، الرائدة عالمياً في مجال المركبات الهجينة والكهربائية، عن دخولها الرسمي إلى سوق دولة الإمارات العربية المتحدة. وجاء الإطلاق خلال أمسية احتفالية راقية أُقيمت في فندق بارك حياة دبي، بحضور عدد من كبار المسؤولين التنفيذيين العالميين في iCAUR، إلى جانب نخبة من كبار الشخصيات وممثلي وسائل الإعلام.


وفي إطار تجربة مستوحاة من الطابع الكلاسيكي، أُتيحت للضيوف فرصة التعرّف عن قرب إلى فلسفة التصميم والهندسة التي تقف خلف طراز V27. وسلّط العرض الضوء على أبرز ملامح المركبة، كاشفاً عن مراحل تطويرها، من الخطوط الخارجية المميّزة والتفاصيل الداخلية الدقيقة، وصولاً إلى التقنيات المتقدمة التي تعزّز أداءها. وقدمت هذه التجربة التفاعلية رؤية متكاملة لا تقتصر على ما تمثّله V27، بل تمتد إلى الأسباب والرؤية التي قادت إلى ابتكارها.


ويقود إطلاق العلامة في منطقة الشرق الأوسط طراز iCAUR V27، وهي سيارة SUV هجينة متكاملة متوسطة إلى كبيرة الحجم، حيث شهدت دبي إطلاقها العالمي الرسمي، إيذاناً بتوافرها للعملاء حول العالم، بعد أن استقطبت اهتماماً واسعاً خلال مشاركتها في عدد من أبرز الفعاليات والمعارض العالمية للسيارات خلال العام الماضي.


وقال تيم تشانغ، المدير العام لشركة شيري إنترناشونال – الشرق الأوسط، خلال حفل الإطلاق: "يعكس الإطلاق العالمي لـ iCAUR من دولة الإمارات التزامنا تجاه المستهلكين في مختلف أنحاء الشرق الأوسط. نحن نحرص على تقديم منتجات رائدة وتجارب راقية تلبي تطلعات الشباب ومن يتمتعون بروح الشباب في المنطقة".


وانسجاماً مع رؤية iCAUR في تقديم «كلاسيكيات الطاقة الجديدة»، يجمع طراز V27 بين تصميم السيارات الرياضية المتعددة الاستخدامات الصندوقي الأصيل وتقنيات الطاقة الجديدة المتقدمة، ليقدّم تجربة قيادة متعددة الاستخدامات، تجمع بين المتانة والأداء المتميّز، سواء داخل المدينة أو على الطرق الوعرة.


وباعتباره الطراز الأبرز للعلامة خلال العام، خضعت سيارة V27 لعمليات تطوير واختبار مكثفة تجاوزت معايير الصناعة المعتمدة. وقبل إطلاقها الرسمي، أجرى فريق تطوير iCAUR اختبارات ميدانية صارمة في كل من دولة الإمارات العربية المتحدة والمملكة العربية السعودية، شملت اختبارات في درجات الحرارة الصيفية القصوى وتجارب قيادة عالية السرعة بين المدن، لضمان جاهزية المركبة للتعامل بثقة مع مختلف ظروف الاستخدام الواقعية.


وخلال مراحل التطوير، تم تشغيل أكثر من 1,000 مركبة اختبار في مواقع متعددة حول العالم، ضمن أكثر من 50 برنامج اختبار شامل. وتجاوز إجمالي مسافات اختبارات المتانة مليون كيلومتر، شملت ظروف الحرارة الشديدة والبرودة القارسة والطرق المعقدة. وتؤكد هذه الاختبارات الشاملة والمتعددة السيناريوهات جاهزية V27 الكاملة لدخول الأسواق العالمية.


وعلى صعيد التصميم، يعتمد طراز V27 فلسفة تصميم كلاسيكية واضحة. إذ يتجاوز طول المركبة خمسة أمتار، مع هيكل صندوقي متناسق، ومصابيح أمامية دائرية كلاسيكية، وأسقف وخطوط مصقولة بعناية، ليحقق توازناً لافتاً بين الطابع القوي واللمسة التكنولوجية العصرية.


أما المقصورة الداخلية، فتتجسّد فيها رؤية “Stellar Cockpit”، التي تضم لأول مرة في فئتها فتحة سقف بانورامية مزدوجة Stellar Porthole مع قدرة حجب للأشعة فوق البنفسجية بنسبة 99.9%، إلى جانب سقف Star Island العائم، ما يوفّر تجربة داخلية رحبة ومتقدمة تقنياً. وبفضل قاعدة عجلات بطول 2,900 ملم والاستغلال الذكي للمساحات، توفّر السيارة ترتيب مقاعد مريحاً لخمسة ركاب.


وعلى مستوى الأداء، يقدّم نظام Golden REEV (السيارة الكهربائية ممتدة المدى) مدى قيادة كهربائياً خالصاً يتجاوز 150 كيلومتراً، ومدى إجمالياً يزيد على 995 كيلومتراً، مع تحقيق توازن مثالي بين القوة والكفاءة، لتلبية متطلبات القيادة داخل المدن والرحلات الطويلة وتعدد سيناريوهات الاستخدام.


وعلى خلاف الأنظمة الهجينة القابلة للشحن التقليدية، يعتمد نظام REEV على محركات كهربائية بالكامل في الدفع، ما يوفّر عزماً فورياً وتسارعاً سلساً، بينما يعمل محرك البنزين حصرياً كمولّد للطاقة عند الحاجة.


وفي إطار تطوير منظومة iCAUR المتكاملة، يأتي طراز V27 مزوّداً بـ 39 منفذاً مدمجاً مسبقاً ضمن منظومة التخصيص، مع مجموعة واسعة من الإكسسوارات وخيارات الترقية التي تعزّز نمط الحياة العصري عالي الجودة للمستخدمين.


وسيحظى عملاء iCAUR في دولة الإمارات بدعم شبكة متكاملة من صالات العرض ومراكز الخدمة. فقد افتتحت العلامة بالفعل صالة العرض الرئيسية في مركز الواحة على شارع الشيخ زايد في دبي، إلى جانب صالات عرض في كل من أبوظبي والشارقة. وتشكل هذه المواقع الثلاثة ركيزة أساسية لخطط iCAUR الطموحة لتوسيع شبكة الوكلاء والتوزيع لتشمل جميع إمارات الدولة السبع.


كما سيتم عرض روبوتات AiMOGA، باعتبارها عنصراً محورياً في منظومة iCAUR، إلى جانب طراز V27 داخل صالات العرض، ما يتيح للزوار اختبار تقنيات عصر الطاقة الجديدة عن قرب.


وأضاف السيد تشانغ: “لدينا رؤية واضحة لسوق دولة الإمارات. فنحن لا نكتفي بافتتاح صالات عرض فحسب، بل نعمل على بناء منظومة متكاملة تشمل خدمات ما بعد البيع بمعايير عالمية، وتأسيس مجتمعات مخصّصة لمالكي المركبات، تتيح لهم تبادل الخبرات، والاستمتاع برحلات مميّزة، والتفاعل مع فرقنا المدربة على أعلى مستوى، وبناء علاقات جديدة.”


وعقب إطلاقه العالمي في دبي، من المقرر أن يصل طراز V27 إلى أسواق ومناطق أخرى حول العالم على مدار العام، ليقدّم للمستخدمين خياراً جديداً يجمع بين الطابع الكلاسيكي وتقنيات الطاقة الجديدة في فئة السيارات الرياضية المتعددة الاستخدامات ذات الهيكل الصندوقي.


لمزيد من المعلومات حول iCAUR V27، يُرجى زيارة الموقع الإلكتروني:


www.icauruae.com



الرابط الثابت

https://aetoswire.com/ar/news/2002202653455


جهات الاتصال

نورا طباع


noura@matrixdubai.com 

iCAUR V27 Makes Its First Global Launch In The UAE

 


iCAUR officially launches, positioning the UAE as a key global strategic market

The brand targets young and young-at-heart consumers.

The V27 redefines the classic SUV with timeless design and dynamic performance, wrapped in cutting-edge technology.

 


iCAUR, a leading hybrid and electric vehicle brand making waves worldwide, has now officially arrived in the UAE. The brand was launched at a glamorous gala evening at the Park Hyatt Dubai, attended by senior global executives from iCAUR, VIP guest,s and respected members of the media.


As part of the classical theme experience, guests were invited to explore the design and engineering philosophy behind the V27. The showcase highlighted key elements of the vehicle, offering an inside look at how the V27 was conceived, designed, and brought to life, from its distinctive exterior form and interior detailing to the advanced technology that powers its performance. This immersive display allowed visitors to understand not just what the V27 is, but why it was created.


Spearheading the brand’s launch in the Middle East is iCAUR’s mid-to-large all-round hybrid SUV, the iCAUR V27, which enjoyed its global launch in Dubai. This marks the official announcement of its availability to customers worldwide, after the model already drew attention at multiple major global automotive events over the past year.


Tim Zhang, General Manager of Chery International Middle East, said at the launch: "iCAUR’s global debut in the UAE reflects our commitment to consumers across the Middle East. We are dedicated to delivering leading products and premium experiences to young and young-at-heart customers in the region."


True to iCAUR’s vision of a new-energy classic, the V27 blends quintessential boxy SUV design with pioneering New Energy technology to deliver a versatile, rugged SUV experience, both in the city and off-road.


As the brand’s flagship release of the year, the V27 has been developed and tested to exceed industry standards in every way. Before its official launch, the iCAUR development team conducted rigorous road testing in the UAE and Saudi Arabia, including extreme summer heat trials and high-speed intercity driving, ensuring the V27 is fully prepared to confidently handle diverse real-world conditions.


During development, more than 1,000 test vehicles were deployed to multiple locations worldwide, completing over 50 comprehensive test programmes. The total durability testing mileage exceeded 1 million kilometres, covering extreme heat, severe cold, and complex road conditions. This full-cycle, multi-scenario validation ensures that the V27 is fully prepared as it enters the market.


On the product side, the V27 adopts a classic design philosophy. At more than five metres long, its boxy profile is paired with classic round headlights and refined surfaces, striking a balance between rugged character and technological aesthetics.


Inside, the “Stellar Cockpit” concept features the class-first Stellar Porthole dual panoramic sun screen with 99.9% UV blockage, and the floating Star Island ceiling, creating a spacious and tech-forward cabin experience. With a 2,900mm wheelbase and efficient use of space, it offers a roomy and comfortable five-seat layout.


In terms of power, the Golden REEV (Range-Extended Electric Vehicle) provides over 150km pure electric range and more than 995km combined range, while balancing performance and efficiency to meet urban, long-distance, and multi-scenario driving needs.


Unlike conventional plug-in hybrids, the REEV system is fully driven by electric motors, delivering instant torque and smooth acceleration, while the gasoline engine functions solely as a generator when required.


Excitingly, iCAUR continues to build its ecosystem of customisations. The V27 comes with 39 pre-installed ecosystem ports and offers a wide range of upgrade accessories to enhance users’ high-quality lifestyle.


UAE customers will be supported with a network of showrooms and service centres. iCAUR has already opened the flagship showroom at Dubai’s Oasis Centre on Sheikh Zayed Road, along with showrooms in Abu Dhabi and Sharjah. These three strategic locations form the basis of iCAUR’s ambitious plans to expand the dealership and distribution network across all seven emirates. 


In addition, as an important member of the iCAUR ecosystem, the AiMOGA Robots will be showcased alongside the V27 in showrooms, allowing users to experience the cutting-edge technology of the new energy era firsthand.


“We have a clear vision for the UAE market – we are not content to simply open showrooms – these locations will be part of a bigger eco-system that includes world class after-sales service and establishing dedicated owner communities, so our valued customers can share experiences, enjoy interesting drives, interact with our highly trained teams and make new friends,” Mr Zhang commented.


Following its global launch in Dubai, the V27 is set to arrive in more countries and regions throughout the year, offering users worldwide a new choice of classic, new-energy boxy SUVs.


For more information on the iCAUR V27, visit www.icauruae.com.



Permalink

https://aetoswire.com/en/news/2002202653454


Contacts

Namita Thakkar - namita@matrixdubai.com

Newmont Reports 2025 Mineral Reserves of 118.2 Million Gold Ounces and 12.5 Million Tonnes of Copper

 DENVER - Friday, 20. February 2026 AETOSWire  




(BUSINESS WIRE)--Newmont Corporation (NYSE: NEM, ASX: NGT, PNGX: NEM) (Newmont or the Company) reported gold Mineral Reserves ("reserves") of 118.2 million attributable ounces at the end of 2025 compared to 134.1 million attributable ounces at the end of 2024, mainly driven by the divestment of assets in 2025. Newmont's portfolio includes significant reserves from other metals, including 12.5 million attributable tonnes of copper reserves and 442 million attributable ounces of silver reserves.


"In 2025, Newmont maintained its position of having the industry's largest gold reserve base, declaring 118 million ounces of reserves, representing decades of production life with meaningful upside," said Natascha Viljoen, Newmont's President and Chief Executive Officer. "Through the disciplined application of technical rigor in our leading exploration program, we remain focused on extending mine life, discovering new opportunities, and unlocking value across our world-class portfolio of operations and projects."


2025 Reserves & Resources Highlights


The gold industry's largest reserve base with 118.2 million attributable ounces1

Changes since 2024 are mainly driven by divestments (8.6 million ounces), followed by depletion from mining, reclassification of the Yanacocha Sulfides project reserves to resources, and cost escalation assumptions, offset by an increased gold price assumption, resource conversion and other positive revisions at Brucejack, Tanami, Lihir, Ahafo North and Ahafo South

Gold reserves are determined based on a gold price of $2,000 per ounce following the annual pricing review, more than 20 percent below the three-year trailing average price and well below the current spot price

Newmont benefits from a premier operating asset base with gold reserve life of ten years or more at Lihir, Cadia, Tanami, Boddington, Ahafo North, Merian, Cerro Negro, Brucejack, Nevada Gold Mines (NGM), and Pueblo Viejo further enhanced by a broader portfolio and organic project pipeline

Measured & Indicated Gold Mineral Resources2 of 88.1 million attributable ounces and Inferred Resources of 60.6 million attributable ounces, determined based on a gold price of $2,300 per ounce

Significant exposure to other metals including 12.5 million attributable tonnes of copper reserves, 13.1 million attributable tonnes of Measured & Indicated copper resources and 5.6 million attributable tonnes of Inferred copper resources, along with 442 million ounces of silver reserves, 508 million ounces of Measured & Indicated silver resources and 126 million ounces of Inferred silver resources

Additional exposure to other metals including lead, zinc and molybdenum

_______________________________________________

1


 

Compared to 2024 reserves disclosed by gold mining companies in 2025


2


 

Exclusive of Mineral Reserves


Percentage of Gold Reserves by Jurisdiction


Newmont’s reserve base is a key differentiator with an operating reserve life of more than ten years at eight managed sites and two non-managed joint ventures, anchored in favorable mining jurisdictions along with significant upside potential from a robust organic project pipeline.


PROVEN & PROBABLE GOLD RESERVES


For 2025, Newmont reported 118.2 million attributable ounces of gold reserves compared to the prior year total of 134.1 million attributable ounces. Divestment of assets accounted for 8.6 million ounces of this reduction3, followed by depletion from mining of 7.2 million ounces, net negative revisions of 5.6 million ounces (primarily from Yanacocha Sulfides reclassified to resource) and cost escalation assumption impacts of 3.1 million ounces, offset by increases from price related revisions of 6.6 million ounces, as well as the addition of 2.0 million ounces from conversion of resources and other additions primarily at Brucejack (+0.7 million ounces) and Lihir (+0.5 million ounces).


_____________________________________________

3


 

Assets divested in 2025 were CC&V, United States; Musselwhite, Canada; Porcupine, Canada; Éléonore, Canada; and Akyem, Ghana.


Managed Assets


Brucejack reserves increased 1.0 million ounces to 2.9 million ounces, primarily due to conversion of resources of 0.7 million, positive net revisions of 0.3 million following favorable drilling results and a favorable price impact of 0.2 million ounces net of cost escalation assumptions, offsetting depletion of 0.2 million ounces

Merian reserves increased 0.4 million ounces to 4.5 million ounces, primarily due to favorable price related revisions of 0.8 million ounces, more than offsetting negative net revisions of 0.2 million ounces and depletion of 0.2 million ounces

Lihir reserves increased 0.2 million ounces to 16.0 million ounces, primarily due to favorable price impacts of 0.8 million ounces and conversion from resources through infill drilling of 0.5 million ounces, partially offset by net negative revisions of 0.3 million ounces offsetting depletion of 0.8 million ounces

Tanami reserves increased 0.2 million ounces to 5.3 million ounces, primarily due to favorable price impacts, net of cost escalation of 0.3 million ounces, additions from net positive revisions of 0.2 million ounces and resource conversion from infill drilling of 0.1 million ounces, more than offsetting depletion of 0.4 million ounces

Ahafo North reserves increased 0.1 million ounces to 4.7 million ounces, primarily due to additions from resources through updated mine designs of 0.2 million ounces, partially offset by depletion of 0.1 million ounces

Red Chris reserves decreased 0.1 million ounces to 3.6 million ounces, primarily due to depletion of 0.1 million ounces

Cerro Negro reserves decreased 0.2 million ounces to 3.0 million ounces, primarily due to depletion of 0.2 million ounces and negative net revisions of 0.1 million ounces, partially offset by 0.1 million ounces of conversions from resources with infill drilling

Ahafo South reserves decreased 0.5 million ounces to 4.1 million ounces, primarily due to the depletion of 0.8 million ounces, partially offset by 0.2 million ounces added at the Apensu South open pit and positive price impacts of 0.1 million ounces

Boddington reserves decreased 0.6 million ounces to 10.2 million ounces, primarily due to depletion of 0.6 million ounces and negative net revisions of 0.1 million ounces, partially offset by favorable price related revisions 0.1 million ounces net of cost escalation assumptions

Cadia reserves decreased 0.6 million ounces to 13.5 million ounces, primarily due to depletion of 0.5 million ounces

Peñasquito reserves decreased 0.9 million ounces to 3.2 million ounces, primarily due to depletion of 0.8 million ounces along with negative net revisions from a block model update of 0.2 million ounces partially offset by favorable price impact of 0.1 million ounces

Yanacocha reserves decreased 4.8 million ounces to 0.5 million ounces, primarily due to the reclassification of 4.5 million ounces of reserves relating to the Yanacocha Sulfides project to resources, allowing Newmont to prioritize other opportunities at site and continue advancing closure activities in non-operating areas

Non-Managed Assets


Newmont’s 38.5 percent interest in Nevada Gold Mines represented 17.4 million attributable ounces of gold reserves at year end, compared to 17.9 million ounces at the end of 2024

Newmont's 40 percent interest in Pueblo Viejo represented 8.2 million attributable ounces of gold reserves at year end with no change from 2024

Newmont's gold grade reserve remained unchanged at 0.94 grams per tonne year over year when adjusted for the divested assets.


GOLD RESOURCES45


At the end of 2025, Newmont reported Measured and Indicated Gold Mineral Resources of 88.1 million attributable ounces, an 11 percent decrease from the prior year total of 99.4 million attributable ounces. Inferred Gold Mineral Resources totaled 60.6 million attributable ounces, a 14 percent decrease from the prior year total of 70.6 million attributable ounces. The main driver of lower resources is 14.6 million ounces removed from assets divested in 20256, together with net negative revisions, net resource conversions to reserves, and updated cost assumptions; partially offset by the resource increases from price assumption related revisions, as well as additions.


Notable Changes7


Cadia resources decreased by 8.5 million ounces (44 percent) to 11.0 million ounces, primarily driven by 5.7 million ounces of net negative revisions related to a geotechnical standoff from the in-pit tailings facility as well as block model updates and changes to inferred resource classifications as a consequence of an updated drill spacing study. An additional 3.0 million ounces of negative impact from higher cost expectations for future caves net of benefits from higher price assumptions

Namosi resources of 5.0 million ounces were removed from resources as Newmont further evaluates the project

Yanacocha resources increased by 4.3 million ounces, primarily driven by 4.5 million ounces reclassified from reserves from Yanacocha Sulfides, aligned with Newmont's decision to indefinitely defer the project

Ahafo South resources increased 45 percent to 7.4 million ounces, primarily driven by 1.7 million ounces of resource additions largely at Apensu underground

Newmont’s Measured and Indicated Gold Mineral Resource grade decreased to 0.58 grams per tonne compared to 0.59 grams per tonne in the prior year. Inferred Gold Mineral Resource increased to 0.9 grams per tonne compared to 0.6 grams per tonne in the prior year, largely due to the removal of inferred resources from Namosi and assets divested.


_______________________________________

4


 

Total resources presented includes Measured and Indicated resources of 88.1 million attributable gold ounces and Inferred resources of 60.6 million attributable gold ounces. See cautionary statement at the end of this release.


5


 

Net Conversion inclusive of ounces reclassified from reserves to resources.


6


 

Assets divested in 2025 were CC&V, United States; Musselwhite, Canada; Porcupine, Canada; Éléonore, Canada; and Akyem, Ghana.


7


 

Includes Measured and Indicated as well as Inferred resources. See detailed tables that follow.


OTHER METALS


Copper reserves decreased slightly to 12.5 million tonnes from 13.5 million tonnes in the prior year, primarily due to reclassification of the Yanacocha Sulfides project to resources. Measured and Indicated copper resources decreased to 13.1 million tonnes from 14.1 million tonnes. Inferred copper resources decreased to 5.6 million tonnes from 11.0 million tonnes driven almost entirely by the removal of Namosi.


Silver reserves decreased to 442 million ounces compared to 530 million ounces in the prior year, primarily due to the reclassification of the Yanacocha Sulfides project to resources and depletion at Peñasquito. Measured and Indicated silver resources increased to 508 million ounces from 469 million ounces in the prior year while inferred silver resources increased to 126 million ounces from 113 million ounces in the prior year; both due to the reclassification of the Yanacocha Sulfides projects.


Lead reserves decreased slightly to 0.7 million tonnes from 0.8 million tonnes primarily due to depletion. Measured and Indicated lead resources were unchanged at 0.5 million tonnes. Zinc reserves decreased to 1.5 million tonnes from 1.7 million tonnes primarily due to depletion. Measured and Indicated zinc resources increased to 1.4 million tonnes from 1.2 million tonnes.


Molybdenum reserves were unchanged at 0.2 million tonnes. Measured and Indicated molybdenum resources remained unchanged at 0.1 million tonnes.


EXPLORATION OUTLOOK


Newmont’s attributable exploration expenditure for managed operations is expected to be approximately $205 million in 2026 with 80 percent of total exploration investment dedicated to near-mine expansion programs and brownfields with the remaining 20 percent allocated to the advancement of greenfield projects.


Additionally, Newmont’s share of exploration investment for its non-managed operations is expected to be approximately $35 million, for a total consolidated exploration expense outlook of $240 million for 2026.


Newmont expects to invest the largest proportion of exploration funds in prospective targets at Merian, Cerro Negro, and Ahafo South.


UPDATED GOLD PRICE FOR MINERAL RESERVES AND MINERAL RESOURCES


As part of the annual Mineral Reserves and Mineral Resources update, Newmont assesses the metal price assumptions used for the calculation of year-end reserves and resources.


In line with market conditions, Newmont has increased its reserves gold price assumption by 18 percent to $2,000 per ounce from $1,700 per ounce in 2024; which is less than 60 percent of the 2025 average realized gold price. Newmont's updated reserves gold price is approximately 23 percent lower than the three-year trailing gold price average of $2,586 per ounce. Historically, over the last ten years (2015 - 2024), Newmont has assumed a reserve price approximately 13 percent below the three year trailing average. Consistent with Newmont's historical approach, the resources gold price has been calibrated higher than reserves to allow identification of the optimum areas to further expand the life of its assets and to target where additional drilling and study work is required at its operating mines. For 2025, mineral resources are based on a $2,300 per ounce.


Newmont's robust internal processes and proven track record of responsibly and rigorously defining reserves and resources will continue to support the development of its world-class portfolio and organic project pipeline.


GOLD RESERVE SENSITIVITY


A $100 increase in gold price would result in an approximate 5 percent increase in gold reserves while a $100 decrease in gold price would result in an approximate 2 percent decrease in gold reserves. These sensitivities assume an oil price of $75 per barrel (WTI), Australian dollar exchange rate of $0.70 and Canadian dollar exchange rate of $0.75. These sensitivities assume all other inputs remain equal, including all cost and capital assumptions, which may also have a material impact on these approximate estimates.


Friday, February 20, 2026

YolTech Therapeutics تعلن عن نتائج مرحلية إيجابية لعقار YOLT-202 المخصص لعلاج مرض عوز ألفا-1 أنتيتريبسين


 

 أدت جرعة واحدة من YOLT-202 إلى زيادات سريعة وقوية ومعتمدة على الجرعة في مستويات بروتين ألفا-1 أنتيتريبسين (AAT)، حيث ارتفعت إلى المعدلات الطبيعية


 أظهرت جرعة واحدة من YOLT-202 قدرة تحمّل جيدة لدى المرضى، مع تسجيل ملف أمان إيجابي ومطمئن


(BUSINESS WIRE)-- أعلنت YolTech Therapeutics، وهي شركة تكنولوجيا حيوية في مرحلة سريرية متقدمة تُركز على تطوير علاجات تحرير الجينات داخل الجسم اليوم عن نتائج مرحلية إيجابية من دراسة سريرية بدأها باحثون (IIT) لعقار YOLT-202، وهو علاج لتحرير القواعد الجينية يُعطى داخل الجسم تجريبي لعلاج مرض عوز ألفا-1 أنتيتريبسين (AATD). وأظهرت البيانات تحقيق نتائج إيجابية من حيث السلامة وقابلية التحمل، إلى جانب زيادات ملموسة وذات دلالة في مستويات بروتين ألفا-1 أنتيتريبسين (AAT) لدى المرضى الذين تلقوا جرعات 35 ملغ و45 ملغ.


 قال الدكتور Yuxuan Wu، الحاصل على دكتوراه في الطب، والمؤسس والرئيس التنفيذي لشركة YolTech Therapeutics: "تمثل هذه النتائج المرحلية محطة مهمة ومُشجعة لكلٍ من YolTech والمرضى الذين يعيشون مع الحالات الشديدة من مرض عوز ألفا-1 أنتيتريبسين (AATD). إن الزيادات السريعة والقوية والمعتمدة على الجرعة في مستويات بروتين AAT الوظيفي التي تم رصدها في هذه الدراسة — لا سيما لدى الأفراد من ذوي النمط الجيني PiZZ — تؤكد الإمكانات التحويلية لتحرير القواعد الجينية داخل الجسم كنهج علاجي يُعطى لمرة واحدة". "لا يقل أهمية عن ذلك ملف السلامة الإيجابي الذي لاحظناه حتى الآن، والذي يعكس الدقة العالية والهندسة المتقدمة التي يستند إليها YOLT-202. وبفضل هذه النتائج، نزداد ثقةً أكثر من أي وقت مضى في الإمكانات الواعدة لعقار YOLT-202 لإعادة صياغة النهج العلاجي لمرض عوز ألفا-1 أنتيتريبسين (AATD). كما نتطلع إلى المضي قدمًا في تطوير هذا البرنامج وصولاً إلى تقديم طلب دواء قيد البحث (IND) إلى إدارة الغذاء والدواء الأمريكية (FDA)، بينما نواصل التزامنا بتطوير علاجات مستدامة تُحدث تأثيرًا حقيقيًا ومُغيرًا لحياة المرضى".


 يخضع YOLT-202 حاليًا للتقييم ضمن دراسة سريرية من نوع "الأولى على البشر"، ومفتوحة التسمية، وتعتمد على تصعيد الجرعة لجرعة واحدة، وذلك لدى مرضى بالغين مصابين بمرض عوز ألفا-1 أنتيتريبسين (AATD). وتهدف الدراسة بشكل أساسي إلى تقييم مستوى السلامة وقابلية التحمل. وحتى تاريخ 6 فبراير، تم تسجيل مشاركين اثنين مؤكدين وراثيًا من ذوي النمط الجيني PiZZ، وتم إعطاؤهما جرعات من YOLT-202 ضمن مجموعتي الجرعة 35 ملغ و45 ملغ.


بعد إعطاء YOLT-202، أظهر كلا المريضين زيادات سريعة وقوية ومعتمدة على الجرعة في مستويات بروتين ألفا-1 أنتيتريبسين (AAT)، وذلك بدءًا من الأسبوع الأول من العلاج. وصلت مستويات بروتين ألفا-1 أنتيتريبسين (AAT) لدى كلا المريضين إلى ما فوق الحد الوقائي البالغ 11 ميكرومول. بالإضافة إلى ذلك، ارتفعت مستويات بروتين ألفا-1 أنتيتريبسين (AAT) إلى النطاق الطبيعي (>20 ميكرومول) في مجموعة الجرعة 45 ملغ. كانت بروتينات ألفا-1 أنتيتريبسين (AAT) الجديدة المنتجة مصححة هيكليًا (M-AAT) ووظيفية، حيث ارتفعت نسبة M-AAT المصححة لتتجاوز 95% لدى المشاركين في مجموعة الجرعة 45 ملغ.


أظهر YOLT-202 ملف سلامة وقابلية تحمّل إيجابي، مع تسجيل أحداث جانبية (AEs) يمكن إدارتها بسهولة. لم يتم الإبلاغ عن أي أحداث جانبية شديدة أو أحداث أدت إلى التوقف عن استخدام YOLT-202، وجميع الأحداث الجانبية المسجلة تم تصنيفها من الدرجة الأولى. وكانت أكثر الأحداث الجانبية شيوعًا هو رد الفعل المرتبط بالحقن (IRR). شهد بعض المرضى ارتفاعًا في إنزيمات الكبد مثل ألانين أمينوترانسفيراز (ALT) وأسبارتات أمينوترانسفيراز (AST)، وكان هذا الارتفاع خفيفًا، غير مصحوب بأعراض، وتعافى سريعًا دون الحاجة لأي دواء.


تواصل الدراسة السريرية التي بدأها الباحثون (IIT) برقم التسجيل NCT07193615 تقييم جرعات فردية من YOLT-202 تُعطى عن طريق التسريب الوريدي بمستويات 35 ملغ و45 ملغ و55 ملغ. تعمل شركة YolTech Therapeutics بنشاط على التحضير لتقديم طلب دواء قيد البحث (IND) إلى إدارة الغذاء والدواء الأمريكية لدعم التطوير السريري العالمي لعقار YOLT-202 لعلاج مرض عوز ألفا-1 أنتيتريبسين (AATD).


 نبذة عن YOLT-202


 YOLT-202 هو علاج لتحرير الجينات داخل الجسم يهدف إلى تصحيح طفرة PiZ إلى PiM لعلاج مرض نقص ألفا-1 أنتيتريبسين (AATD). باستخدام محرر قواعد الجينات الخاص بشركة YolTech Therapeutics، تم تصميم YOLT-202 لتحقيق تحرير دقيق على الهدف مع الحد الأدنى من النشاط الجانبي على مواقع أخرى في الجينوم. ويتم حاليًا دراسة YOLT-202 ضمن تجربة سريرية أولية قائمة في الأساس على البشر مصممة لتقييم السلامة وقابلية التحمل بالإضافة إلى تحديد الجرعة البيولوجية المثلى لدى المرضى المصابين بـ AATD. وقد حصل YOLT-202 سابقًا على تصنيف دواء للأمراض النادرة من إدارة الغذاء والدواء الأمريكية، وتعمل الشركة حاليًا على التحضير لتقديم طلب دواء قيد البحث (IND) إلى إدارة الغذاء والدواء الأمريكية لدعم التطوير السريري المستقبلي لعقار YOLT-202.


 نبذة عن مرض عوز ألفا-1 أنتيتريبسين (AATD)


يُعد نقص ألفا-1 أنتيتريبسين (AATD) اضطرابًا وراثيًا موروثًا، سائدًا مشتركًا، ينشأ عن طفرات في جين SERPINA1، وأشهر المتغيرات الناقصة تأتي من الأليل Z (Glu342Lys) والأليل S (Glu264Val). يؤدي وجود الأليل Z إلى خلل في طي بروتين ألفا-1 أنتيتريبسين (AAT) وتكوّن بوليمرات غير طبيعية، مما يجعل أكثر من 95% من المرضى المصابين بالحالات الشديدة من AATD يحملون النمط الجيني PiZZ.


 نبذة عن YolTech


صُمِّمت علاجات شركة YolTech Therapeutics على منصة HEPDONE™ للمحرر الجديد وتقنيات الجسيمات الدهنية غير الفيروسية، وتُعدّ الشركة رائدة في تطوير أدوية تحرير الجينات داخل الجسم التي تهدف إلى توفير علاج لمرة واحدة يمنح فوائد مستدامة مدى الحياة. ويستهدف خط التطوير السريري المتوسع للشركة أمراضًا وراثية، وأيضية، وقلبية وعائية، ومناعية ذاتية، مع نتائج أولية تدعم الإمكانات لتحقيق فوائد علاجية دائمة وتحويلية للمرضى.


 تابع آخر المستجدات من شركة YolTech Therapeutics:

LinkedIn: linkedin.com/company/yoltech-therapeutics

 الموقع الإلكتروني: www.yoltx.com


إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.



الرابط الثابت

https://www.aetoswire.com/ar/news/2002202653466


جهات الاتصال

 YolTech Therapeutics

 Ally Yu

 xiaolingyu@yoltx.com


 Precision AQ

 Andrew Dymon

 andrew.dymon@precisionaq.com


YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency


 

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range


Single dose of YOLT-202 was well tolerated with a favorable safety profile


(BUSINESS WIRE) -- YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels.


“These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as a one‑time treatment approach,” stated Yuxuan Wu, M.D., Founder and CEO of YolTech Therapeutics. “Equally encouraging is the favorable safety profile we have seen to date, which reinforces the precision and thoughtful engineering behind YOLT‑202. With these results in hand, we are more confident than ever in YOLT‑202’s potential to redefine the treatment paradigm for AATD, and we look forward to advancing this program toward an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) as we continue our mission to bring durable, life‑changing therapies to patients.”


YOLT-202 is being evaluated in a first-in-human, open-label, single dose escalation study in adult AATD patients, aiming to evaluate safety and tolerability. As of February 6th, two participants genetically confirmed as PiZZ genotype, were enrolled and dosed with YOLT-202 in both the 35 mg and 45 mg dose groups.


Following administration of YOLT-202, both patients showed rapid, robust and dose-dependent increases in AAT level as early as in Week 1. AAT levels in both patients reached above the protective threshold of 11 μM. Additionally, AAT levels increased to normal range (>20 μM) in the 45 mg dose group. These newly produced AAT proteins were both structurally corrected (M-AAT) and functional, with the proportion of corrected M-AAT increasing to >95% in the 45 mg dose group.


YOLT-202 demonstrated favorable safety and tolerability with manageable adverse events (AEs). No severe AEs or AEs leading to discontinuation of YOLT-202 were reported, and all AEs were classified as Grade 1. The most common AE was infusion-related reaction (IRR). Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were asymptomatic, mild and soon recovered without medication.


The ongoing IIT study (NCT07193615) is evaluating single doses administered via intravenous infusion of YOLT-202 at 35 mg, 45 mg and 55 mg dose levels. YolTech is actively preparing to file an IND with the FDA to support the global clinical development of YOLT-202 in AATD.


About YOLT-202


YOLT-202 is an in vivo gene-editing therapy that corrects PiZ mutation to PiM for the treatment of AATD. Utilizing YolTech’s proprietary adeneine base editor, YOLT-202 is engineered to achieve on-target editing with minimal bystander activity. YOLT-202 is currently being investigated in a first-in-human IIT study designed to evaluate safety and tolerability as well as an optimal biological dose of YOLT-202 in subjects with AATD. YOLT-202 has previously been granted Orphan Drug Designation by the U.S. FDA and the Company is currently preparing to file an IND with the U.S. FDA to support clinical development of YOLT-202.


About Alpha-1 Antitrypsin Deficiency (AATD)


AATD is an inherited, genetic, autosomal co-dominant disorder caused by mutations in the SERPINA1 gene, with the most frequent deficient variants coming from the Z (Glu342Lys) and S alleles (Glu264Val). The presence of Z alleles results in misfolding and polymerization of the AAT, leading to over 95% of severe AATD patients being PIZZ.


About YolTech


Built on HEPDONE™ Novel Editor Platform and non-viral LNP technologies, YolTech Therapeutics is pioneering in vivo gene-editing medicines with the potential for a one-time treatment that provides lifelong benefit. The company’s expanding clinical pipeline targets genetic, metabolic, cardiovascular, and autoimmune diseases, with initial results supporting the potential for durable and transformative therapeutic benefit.


Stay informed with the latest from YolTech Therapeutics:

LinkedIn: linkedin.com/company/yoltech-therapeutics

Website: www.yoltx.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260219197004/en/



Permalink

https://www.aetoswire.com/en/news/1902202653423


Contacts

YolTech Therapeutics

Ally Yu

xiaolingyu@yoltx.com


Precision AQ

Andrew Dymon

andrew.dymon@precisionaq.com